⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ARWR News
Arrowhead Research Corporation
Atherosclerotic Cardiovascular Disease Market to Register Incremental Growth at a CAGR of 4.9% During the Forecast Period (2025–2034) | DelveInsight
globenewswire.com
AMGN
ARWR
IONS
NVS
NVO
MRK
LLY
REGN
ESPR
ALNY
VRTX
XBI
Arrowhead Pharmaceuticals Prices Upsized Offerings of Convertible Senior Notes, Common Stock and Pre-Funded Warrants
businesswire.com
ARWR
Arrowhead Pharmaceuticals Announces NMPA Approval of REDEMPLO ® (plozasiran) for Familial Chylomicronemia Syndrome (FCS) in China
businesswire.com
ARWR
Arrowhead Pharmaceuticals Announces Proposed Offerings of Convertible Senior Notes and Common Stock
businesswire.com
ARWR
Arrowhead Pharmaceuticals Announces Interim Clinical Data on RNAi-based Obesity Candidates Showing Weight Loss in Obese Patients with Diabetes and Improved Measures of Body Composition
businesswire.com
ARWR
Arrowhead Pharmaceuticals annonce l’approbation de REDEMPLO MC (plozasiran) par Santé Canada pour réduire les triglycérides chez les adultes atteints du syndrome de chylomicronémie familiale (SCF)
businesswire.com
ARWR
Arrowhead Pharmaceuticals Announces Health Canada Approval of REDEMPLO™ (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)
businesswire.com
ARWR
Arrowhead Pharmaceuticals to Participate in Upcoming January 2026 Events
businesswire.com
ARWR
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies
businesswire.com
ARWR
Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran in Severe Hypertriglyceridemia
businesswire.com
ARWR